News
President Kim Brooks, Dr. Pat Croskerry appointed to Order of Canada
The latest set of appointments to one of Canada's highest honours has a number of familiar Dal faces, including President Kim Brooks and retired Faculty of Medicine faculty member Dr. Pat Croskerry. Read more.
Featured News
Friday, December 19, 2025
Our 2025 Year in Review brings together 45 stories of innovation, achievement, and community, offering a vivid snapshot of the moments and milestones that helped shape a transformative year.
Wednesday, December 17, 2025
Ä¢¹½AV leapt forward in the 2025 Global Ranking of Academic Subjects, with impressive gains across multiple disciplines.
Wednesday, November 19, 2025
From varsity swimming to ocean-tech entrepreneurship, Isaac Bahler’s path to Oxford reflects a passion for turning climate research into real-world solutions.
Archives - News
Thursday, July 6, 2023
A governance expert, a labour leader, a refugee lawyer, a provincial court judge, a distinguished health professor, a medical researcher, and an ocean engineer are the latest Dal alumni to receive Canada's highest civilian honour.
Wednesday, July 5, 2023
Hollo Medical co-founder David Hodgson's victory brings added recognition to the startup's key innovation — a unique pocket-size asthma inhaler chamber — and provides a huge boost to the company's goal of making it accessible as quickly as possible.
Wednesday, June 28, 2023
One of Nova Scotia’s most prominent community and business leaders, Rustum Southwell — best known as founding CEO of the renowned Black Business Initiative — is set to take on the mantle of Ä¢¹½AV's top ceremonial role. For Southwell, it represents another chapter in a legacy of lifting people up to grow, thrive and succeed.
Wednesday, June 28, 2023
Now ranked at 298 globally, Ä¢¹½AV maintained twelfth place among Canadian universities and remains the top-ranked university in Atlantic Canada.
Tuesday, June 27, 2023
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.